J
Joanne B. Severe
Researcher at National Institutes of Health
Publications - 63
Citations - 20751
Joanne B. Severe is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Attention deficit hyperactivity disorder & Randomized controlled trial. The author has an hindex of 43, co-authored 61 publications receiving 19388 citations. Previous affiliations of Joanne B. Severe include Duke University & University of California, Irvine.
Papers
More filters
Journal ArticleDOI
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Jeffrey A. Lieberman,T. Scott Stroup,Joseph P. McEvoy,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Richard S.E. Keefe,Sonia M. Davis,C.E. Davis,Barry D. Lebowitz,Joanne B. Severe,John K. Hsiao +12 more
TL;DR: Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
Journal ArticleDOI
Diagnostic Interview for Genetic Studies: Rationale, Unique Features, and Training
John I. Nurnberger,Mary C. Blehar,Charles A. Kaufmann,Carolyn York-Cooler,Sylvia G. Simpson,Jill M. Harkavy-Friedman,Joanne B. Severe,Dolores Malaspina,Theodore Reich +8 more
TL;DR: The DIGS is designed to be employed by interviewers who exercise significant clinical judgment and who summarize information in narrative form as well as in ratings, and should be useful as part of archival data gathering for genetic studies of major affective disorders, schizophrenia, and related conditions.
Journal ArticleDOI
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
John S. March,Susan G. Silva,Stephen Petrycki,John F. Curry,Karen C. Wells,John A. Fairbank,Barbara J. Burns,Marisa Elena Domino,Steven McNulty,Benedetto Vitiello,Joanne B. Severe +10 more
TL;DR: The combination of fluoxetine with CBT offered the most favorable tradeoff between benefit and risk for adolescents with major depressive disorder.
Journal ArticleDOI
Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment.
James M. Swanson,Helena C. Kraemer,Stephen P. Hinshaw,L. Eugene Arnold,C. Keith Conners,Howard Abikoff,Walter Clevenger,Mark Davies,Glen R. Elliott,Laurence L. Greenhill,Lily Hechtman,Betsy Hoza,Peter S. Jensen,John S. March,Jeffrey H. Newcorn,Elizabeth B. Owens,William E. Pelham,E. Schiller,Joanne B. Severe,Steve Simpson,Benedetto Vitiello,Karen C. Wells,Timothy Wigal,Min Wu +23 more
TL;DR: These secondary analyses confirm the primary findings and clarify clinical decisions about the choice between multimodal and unimodal treatment with medication.
Journal ArticleDOI
ADHD Comorbidity Findings From the MTA Study: Comparing Comorbid Subgroups
Peter S. Jensen,Stephen P. Hinshaw,Helena C. Kraemer,Nilantha Lenora,Jeffrey H. Newcorn,Howard Abikoff,John S. March,L. Eugene Arnold,Dennis P. Cantwell,C. Keith Conners,Glen R. Elliott,Laurence L. Greenhill,Lily Hechtman,Betsy Hoza,William E. Pelham,Joanne B. Severe,James M. Swanson,Karen C. Wells,Timothy Wigal,Benedetto Vitiello +19 more
TL;DR: Three clinical profiles are indicated, ADHD co-occurring with internalizing disorders (principally parent-reported anxiety disorders) absent any concurrent disruptive disorder (ADHD + ANX), ADHD Co-occurred with ODD/CD but no anxiety (AD HD + ODD /CD), and ADHD with both anxiety and O DD/CD may be sufficiently distinct to warrant classification as ADHD subtypes different from "pure" ADHD with neither comorbidity.